326 results about "Osteosarcoma" patented technology

The invention discloses a polypeptide and application thereof in preparation of a medicine for preventing and / or treating cancers. The amino acid sequence of the polypeptide is shown as SEQ ID No. 1 or SEQ ID No. 2. The cancer is at least one of breast cancer, colorectal cancer, leukemia, esophageal cancer, pancreatic cancer, brain glioma, kidney cancer, skin cancer, osteosarcoma, ovarian cancer and prostate cancer. The invention designs and synthesizes the polypeptide of a targeted staphylococcus tumor protein compound SND1-MTDH containing a nuclease structural domain 1 (SND1 and a heteromucin (MTDH), finds that the polypeptide has excellent inhibitory activity on various different types of human cancer cells for the first time, and provides an optional scheme for broad-spectrum anti-cancer drugs. The polypeptide applied in the invention is simple in synthesis process and low in production cost.

The invention discloses a tryptamine compound as well as a preparation method and application thereof. The tryptamine compound can be used for preparing medicines for preventing and / or treating cancers. The cancer is at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer. According to the invention, activity screening is carried out on a plurality of compounds, the three tryptamine compounds provided by the invention are found to have excellent inhibitory activity on a plurality of different types of human cancer cells for the first time, and an optional scheme is provided for broad-spectrum anti-cancer drugs.

The invention relates to the field of natural products, in particular to a dimer compound of guaiane type sesquiterpenes and uric acid as well as an extraction and separation method and application of the dimer compound. According to the invention, a new dimer compound of guaiane type sesquiterpene and uric acid is extracted and separated from carpesium abrotanoides in Guizhou, and it is found that the dimer compound has relatively strong anti-tumor activity. The compound has strong inhibitory activity on breast cancer, prostate cancer, nasopharynx cancer, liver cancer, lung cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, skin cancer, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer, and provides an optional scheme for broad-spectrum anti-cancer drugs. Moreover, in human prostate cancer cells PC3, human cervical cancer cells Hela, human liver cancer cells HepG2 and human glioma cells U87 which are resistant to paclitaxel, the compound also shows strong anti-cancer activity, which indicates that the compound has the potential of treating patients resistant to paclitaxel.

The invention discloses sesquiterpenoids as well as a preparation method and application thereof. The structure of the sesquiterpenoids is shown in the specification. The sesquiterpenoids of # imgabs0 can be used for preparing drugs for preventing and / or treating cancers, and the cancers comprise at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, kidney cancer and skin cancer. According to the invention, various natural product extracts are subjected to activity screening, the sesquiterpenoids derived from the rattan chrysanthemum have excellent inhibitory activity on various different types of human cancer cells, and an optional scheme is provided for broad-spectrum anti-cancer drugs. The sesquiterpenoids applied in the invention are derived from rattan chrysanthemum, the source is wide, and the production cost is low.

The invention belongs to the field of biomedical materials, and particularly discloses a preparation method and application of a 3D printing porous composite scaffold. I-type collagen and silk fibroin composite gel is modified on a 3D printing three-element doped hydroxyapatite / polycaprolactone (PCL) composite scaffold with a polydopamine coating, the three-element doped hydroxyapatite is synthesized by using a chemical precipitation method, and Mg < 2 + >, Sr < 2 + > and SeO3 < 2-> ions are doped in crystal lattices. The 3D printing porous composite scaffold provided by the invention effectively simulates the structure and function of soft and hard combination of natural bones, is helpful for regulating and controlling the stem cell fate to improve the bone regeneration process, repairs bone defects while eliminating tumors, and can be applied to bone defect repair or osteosarcoma treatment.

The invention discloses a near-infrared light response titanium-based implant as well as a preparation method and application thereof, and belongs to the technical field of medical materials. The near-infrared light response titanium-based implant provided by the invention comprises a porous titanium substrate, the TiO2 nanotube array is formed on the surface of the porous titanium substrate; the first photo-thermal coating layer is formed on the TiO2 nanotube array; the second photo-thermal coating is formed on the first photo-thermal coating; wherein the first photo-thermal coating is a ZIF-8 coating; and the second photo-thermal coating is a carbon nanotube coating. Through the double-layer photo-thermal system design of the ZIF-8 coating, the photo-thermal conversion efficiency is greatly improved, the controllable photo-thermal response capacity, the long-acting antibacterial and anti-tumor capacity and the dynamic osseointegration capacity are achieved, and the excellent osteosarcoma treatment effect is achieved.

This invention relates to the field of anticancer drugs, and more particularly to an indole-3-aryl ketone derivative, its preparation method, and its applications. The indole-3-aryl ketone derivative is compound I-VI, which can be used to prepare drugs for the prevention and / or treatment of cancer, including at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer, and esophageal cancer. This invention screened the activity of various compounds and, for the first time, discovered that compound I-VI exhibits excellent inhibitory activity against multiple different types of human cancer cells, providing a potential option for broad-spectrum anticancer drugs.

The invention belongs to the technical field of osteosarcoma prognosis prediction, and relates to a multi-view TSK deep learning model based on Dirichlet distribution and application thereof, a multi-view data module in the model transmits view features to a multi-view TSK fuzzy system module, and the multi-view TSK fuzzy system module maps the input view features into Dirichlet evidence parameters and transmits the Dirichlet evidence parameters to a Dirichlet distribution module; the Dirichlet distribution module establishes a classification probability representation space according to Di richlet evidence parameters and transmits the classification probability representation space to the uncertainty quantification module, the uncertainty quantification module quantifies the classification probability into view decision confidence through a dynamic evidence aggregation engine, self-adaptive weighted fusion is carried out on the view decision confidence through a combination rule, and the view decision confidence is obtained. And a multi-view TSK deep learning model is applied to osteosarcoma prognosis prediction, so that the prediction accuracy is improved.

The present invention addresses the problem of developing a novel medicine for treating osteosarcoma. The present invention also addresses the problem of developing a therapy marker for examining the therapeutic effect of medicine in the treatment of osteosarcoma.　According to the present invention, in order to solve the problems, a compound capable of inhibiting the proliferation of osteosarcoma cells has been discovered and it has been demonstrated that a novel pharmaceutical composition for treating osteosarcoma can be provided. Furthermore, it has been found that the osteosarcoma to be treated with a novel pharmaceutical composition is osteosarcoma in which the number of gene copies of MCL1 gene is increased or the production of Mcl-1 protein is increased in cells or osteosarcoma in which the number of gene copies of BCL2L1 gene is increased or the production of Bcl-xL protein is increased in cells, and it has been demonstrated that a therapy marker for examining the therapeutic effect of the novel pharmaceutical composition in the treatment of osteosarcoma can be provided by detecting each of the above-mentioned increased events.

The invention discloses a limonin compound and application thereof in preparation of a medicine for preventing and / or treating cancers. The structure of the limonin compound is shown as a formula I or II. The cancer is at least one of breast cancer, liver cancer, gastric cancer, esophageal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, prostatic cancer, nasopharynx cancer, cervical cancer, ovarian cancer, kidney cancer and skin cancer. According to the invention, activity screening is carried out on various natural product extracts, it is found for the first time that limonin compounds with structural formulas I and II have excellent inhibitory activity on various different types of human cancer cells, and an optional scheme is provided for broad-spectrum anti-cancer drugs. Related results also show that the compound provided by the invention can inhibit migration and invasion ability of breast cancer cells, promote cell apoptosis and retard a cell cycle. The limonin compound applied in the invention is derived from mallotus oblongifolius, the source is wide, and the production cost is low.

The invention belongs to the technical field of medicinal chemistry, and discloses a paeonol mannich base-rhein conjugate as well as a preparation method and application thereof. The conjugate is a compound as shown in a general formula (I) or (II) or a pharmaceutically acceptable salt thereof. Compared with the clinically common antitumor drugs fluorouracil and paeonol, the conjugate provided by the invention has obviously higher in-vitro anti-human hepatoma carcinoma cell (HepG2) and human lung cancer cell (A549) proliferative activity, and the in-vitro anti-human cervical carcinoma cell (Hela), human colon cancer cell (HT29) and human osteosarcoma cell (U2OS) proliferative activity of most compounds is obviously superior to that of fluorouracil and paeonol; and the conjugate has good water solubility, is expected to be applied to treatment of various cancers such as cervical cancer, colon cancer, osteosarcoma, lung cancer or liver cancer, and has a wide clinical application prospect. # imgabs0 #

The invention discloses a polydopamine modified and cupric peroxide loaded ZIF8 nano particle and application thereof, and belongs to the technical field of medicine preparation. According to the invention, a zeolite imidazoline framework 8 is used as a matrix, CuO2NPs is uniformly modified in the zeolite imidazoline framework 8 to form CuO2 (at) ZIF8NPs, and the surface of the CuO2 (at) ZIF8NPs is coated with a polydopamine film in the form of a film. The invention constructs multifunctional ZIF8NPs (CuO2 (at) ZIF8 (at) PDANPs) which is coated with PDA and loaded with CuO2NPs, and the multifunctional ZIF8NPs (CuO2 (at) ZIF8 (at) PDANPs is used for CDT of thermal enhancement OS. The CuO2 (at) ZIF8 (at) PDA NPs is combined with a photothermal effect and a chemodynamic therapy, shows good biocompatibility and an anti-tumor curative effect, has a potential application prospect in the aspect of osteosarcoma, and provides a new thought and method for treatment of osteosarcoma.

The invention relates to the technical field of image recognition, in particular to an osteosarcoma image intelligent recognition and classification method and system based on an image recognition model. The method comprises the following steps: collecting a tumor image and carrying out multi-sequence disturbance equilibrium enhancement to generate an enhanced block tumor image, then obtaining a color standardized image through color space transformation remapping, then extracting a tumor region image and carrying out contrast inversion processing, reconstructing a tumor feature image, and finally, carrying out multi-sequence disturbance equilibrium enhancement on the tumor feature image. Based on a preset image recognition model, tumor edge features are recognized, the edge rule degree is determined, preliminary classification is carried out, a benign tumor image is obtained, surrounding metabolite signal features of the benign tumor image are analyzed, a benign reference group is formed through combination, metabolism state comparison is carried out on tumor feature images, and metabolism difference data are generated. And performing category correction according to the metabolic state mapping data so as to identify the osteosarcoma category. According to the invention, intelligent analysis of tumor features is realized, the image processing flow is optimized, and the processing efficiency is improved.

The invention relates to the field of anti-cancer drugs, in particular to an indole-3-aryl ketone derivative as well as a preparation method and application thereof. The indole-3-aryl ketone derivative is a compound I-VI, the indole-3-aryl ketone derivative can be used for preparing drugs for preventing and / or treating cancers, and the cancers comprise at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer. According to the invention, activity screening is carried out on various compounds, the fact that the compounds I-VI have excellent inhibitory activity on various different types of human cancer cells is found for the first time, and an optional scheme is provided for broad-spectrum anti-cancer drugs.

There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly ovarian cancer, osteosarcoma, colon cancer, breast cancer, skin cancer, melanoma, esophageal cancer, esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESSC), particularly esophageal cancer, or EAC or ESSC.

The present disclosure generally relates to compositions and methods for treating a disease or condition associated with insufficient opening of Cx43 hemichannels in osteocytes, preferably for treating cancer, cancer metastasis, osteosarcoma, osteoporosis, or osteopenia.

The invention discloses a pelvic soft osteosarcoma MRI (Magnetic Resonance Imaging) segmentation method based on edge-guided multi-scale fusion. The method comprises the following steps: firstly, acquiring an MRI image of a patient with soft osteosarcoma of pelvis, and preprocessing the image; and then, constructing a pelvic soft osteosarcoma MRI segmentation network model, namely an EMU-Net segmentation network, based on edge-guided multi-scale fusion. And training the network by using the preprocessed training data, inputting a pelvic soft osteosarcoma MRI image to be segmented into the trained network, outputting a corresponding segmentation probability graph, and obtaining a final tumor segmentation mask by setting a threshold value. The method not only effectively overcomes the clinical segmentation bottleneck, but also realizes full-automatic and high-efficiency precise segmentation by means of an end-to-end deep learning architecture, and has remarkable advantages in the aspects of precision and robustness.

The invention belongs to the field of biomedical materials, and particularly discloses a preparation method and application of a 3D printing porous composite scaffold. I-type collagen containing growth factors and silk fibroin composite gel are modified on a 3D printing three-element doped hydroxyapatite / polycaprolactone (PCL) composite scaffold with a polydopamine coating, the three-element doped hydroxyapatite is synthesized by using a chemical precipitation method, and Zn < 2 + >, Sr < 2 + > and SeO < 3-> ions are doped in crystal lattices. The 3D printing porous composite scaffold provided by the invention effectively simulates the structure and function of soft and hard combination of natural bones, is helpful for regulating and controlling the stem cell fate to improve the bone regeneration process, repairs bone defects while eliminating tumors, and can be applied to bone defect repair or osteosarcoma treatment.

The invention discloses application of neutrophile granulocyte number level in prediction of tumor treatment effect. Through verification of the embodiment of the invention, the number level of neutrophils in blood of a tumor patient before treatment is closely associated with the curative effect of tumor treatment, especially OH2 treatment, and the applicable tumor adaptation diseases are common; comprising at least one of melanoma, esophageal cancer, right breast invasive ductal cancer, intestinal cancer, head and neck tumor, gastric cancer, ovarian cancer, biliary system tumor, left foot back squamous cell carcinoma, sarcoma and osteosarcoma, lung cancer, thymosquamous cell carcinoma and brain glioma. In the application disclosed by the invention, the threshold value of the number of neutrophils for predicting the tumor treatment effect is 3.5 * 10 < 9 > / L; the treatment is predicted to be effective when the number of sexual granulocytes in a tumor patient is below 3.5 * 109 / L before the tumor patient is treated, and the treatment is predicted to be ineffective or invalid when the number of sexual granulocytes in the tumor patient is higher than 3.5 * 109 / L. The application method is simple, low in cost and good in stability, and can become a potential prediction means for clinicians.

The invention relates to the technical field of image recognition, in particular to a multi-scale osteosarcoma CT image lesion area detection method based on feature distillation. The method comprises the following steps: acquiring a multi-scale osteosarcoma CT image and an attachment area image, performing forged image difference reduction to generate a unified CT image, reconstructing a three-dimensional tumor body form, extracting a bone attachment structure, performing relocation registration to obtain tumor body relocation data, and then generating a simulation attachment area framework based on the data, the method comprises the following steps: performing static feature distillation on a three-dimensional tumor body form to obtain an edge contour, defining an initial attachment area frame, performing feature comparison through a historical contour image to extract form change, evaluating the erosion degree of the attachment frame, and finally screening candidate lesion areas and positioning osteosarcoma lesion areas according to change areas. According to the invention, more efficient multi-source heterogeneous image data integration, more accurate three-dimensional tumor simulation reconstruction and clearer lesion area detection are realized.

The invention discloses a pharmaceutical composition for treating osteosarcoma and application of the pharmaceutical composition, and particularly belongs to the field of biological medicine. The pharmaceutical composition comprises cis-platinum and daidzin, the daidzin provided by the invention is combined with beta-catenin protein, so that the protein stability of the beta-catenin protein is reduced, and a Wnt signal channel is further inhibited, so that the activity of osteosarcoma cells is inhibited, cell apoptosis is induced, and pulmonary metastasis is inhibited; the pharmaceutical composition of cis-platinum and daidzin provided by the invention has a synergistic effect, the sensitivity of cells to cis-platinum is remarkably improved, and the daidzin and cis-platinum combined medication has a remarkable inhibition effect on the activity and migration invasion ability of osteosarcoma cells.

The invention relates to the field of antitumor drugs, in particular to a thiophene acetyl tetrahydro-beta-carboline compound and application thereof. The thiophene acetyl tetrahydro-beta-carboline compound or the pharmaceutically acceptable salt thereof, and the pharmaceutical composition containing the compound can be used for preparing medicines for preventing and / or treating various cancers. The cancer is at least one of breast cancer, lung cancer, osteosarcoma, melanoma, gastric cancer, pancreatic cancer, kidney cancer, glioma and ovarian cancer. Activity screening is carried out on various compounds, it is found for the first time that the 12 compounds provided by the invention have remarkable broad-spectrum inhibitory activity on various human cancer cell lines, and key candidate compounds are provided for developing novel anti-cancer drugs.

The invention belongs to the field of cell culture, and discloses an osteosarcoma organ culture medium and a gelatin planting method. The following components are added into the osteosarcoma organ-like culture medium: a B27 additive, an N-2 additive, a GlutaMAX additive, casein amino acid, N-acetylcysteine, nicotinamide, vitamin C, sodium pyruvate, human gastrin, Wnt3A, R-spondin 1 protein, Noggin protein, activin A protein, Forskolin, Y-27632, SB202190, CHIR99021, A83-01, h-EGF, FGF-10, HGF, VEGF A, IGF 1, IL-6, cyan-streptomycin and fetal calf serum. The osteosarcoma organoid culture medium provided by the invention can promote organoid cells to maintain relatively high multiplication capacity and maintain self-renewal, so that the amplification efficiency and the modeling success rate of the organoid are greatly improved.

The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and / or preventing proliferative diseases (e.g., cancers (e.g., leukemia, acute lymphoblastic leukemia, lymphoma, Burkitt's lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer, colorectal cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7)), and therefore, induce cellular apoptosis and / or inhibit transcription in the subject.

The invention relates to application of an SLC30A9 inhibitor in preparation of an anti-tumor medicine, and belongs to the technical field of biological medicines. The invention provides an application of an SLC30A9 inhibitor in preparation of an anti-tumor drug. The expression of SLC30A9 is down-regulated to activate a cGAS-STING-NF-kappa B pathway, so that apoptosis of osteosarcoma cells is promoted, killing of the osteosarcoma cells by MTX is enhanced, and sensitivity of the osteosarcoma cells to MTX chemotherapy is recovered. Through combined application of SLC30A9 knock-down, a cGAS-STNG-NF-kappa B pathway agonist and MTX for chemotherapy, the killing effect of MTX on osteosarcoma cells can be remarkably enhanced, tumor cell proliferation is inhibited, and the treatment effect is improved. The core effect of the SLC30A9 in an osteosarcoma chemotherapy drug resistance mechanism is defined, and a theoretical basis and a technical support are provided for subsequent development of targeted drugs aiming at a cGAS-STNG-NF-kappa B pathway.

The present invention discloses a method and system for detecting lesion areas in osteosarcoma CT images based on feature correlation, which relates to image technology in the medical field. The method includes: obtaining osteosarcoma CT images and making a data set; constructing a target detection model based on feature correlation and using the data set for training, and using the trained target detection model to realize lesion area detection in osteosarcoma CT images. The target detection model is a convolutional neural network, and the Backbone part includes a number of alternating modules connected in sequence for extracting features; the Neck part uses a mutually fused FPN network and a PANET network to receive the output of the Backbone part and output multiple dimensional feature maps; the Head part receives the multiple dimensional feature maps output by the Neck part and outputs a detection image based on global information. The present invention uses a combination of knowledge distillation and target detection to optimize the problem of false detection and missed detection in osteosarcoma CT images, and improve the recognition rate and accuracy of detection.

GD2 specific chimeric antigen receptor effector cells for the treatment of solid tumors, possibly in combination with an enhancer of a Zeste homolog 2 (EZH2) inhibitor. The invention relates to a GD2-specific chimeric antigen receptor (GD2. CAR) effector cell for use in the treatment of solid tumors, in particular in the treatment of extracranial GD2 + tumors, such as soft tissue sarcoma and osteosarcoma, neuroblastoma, melanoma, lung cancer, bladder cancer and retinoblastoma, and brain tumors. In addition, the present invention also relates to the use of the GD2. CAR genetically modified effector cell in combination with an enhancer of a Zeste homolog 2 (EZH2) inhibitor for the treatment of solid tumors.

Aspects of this invention are related to the use of N-desmethyl ruboxistaurin and pharmaceutically acceptable formulations thereof to modulate RSK signaling. Some aspects of the invention relate to the use of N-desmethyl ruboxistaurin to inhibit RSK. Some aspects of the invention provide methods of using N-desmethyl ruboxistaurin in the treatment of subjects with cancer, including breast cancer, ovarian cancer, prostate cancer, lung cancer, hepatocellular carcinoma, colorectal cancer, melanoma, osteosarcoma, myeloproliferative neoplasms, leukemia, and bladder cancer. The disclosed methods extend beyond disease treatment, including supportive care during radiation chemotherapy and prevention of cancer relapse. N-desmethyl ruboxistaurin administration, alone or in combination with other cancer therapies, inhibits RSK and shows a safety profile that supports its long-term use.

The present invention discloses an osteosarcoma molecular marker and its application. The osteosarcoma molecular marker is spindle and centriole associated protein 1, the amino acid sequence of which is shown in SEQ ID No: 1. Tissue sequencing revealed that the expression level of spindle and centriole associated protein 1 having the amino acid sequence of SEQ ID No: 1 was significantly higher in osteosarcoma tissue than in normal bone tissue. After knocking down the protein, osteosarcoma proliferation, invasion, and migration were significantly inhibited, and apoptosis was increased. Therefore, the molecular marker can be used as an osteosarcoma marker, playing a role in assisting the diagnosis of osteosarcoma in its early stages, enabling patients to receive timely treatment and preventing the problem of osteosarcoma metastasis.

This disclosure provides compounds of formula (I) or pharmaceutically acceptable salts thereof, methods for preparing the same, and their use in the treatment and / or diagnosis of cancers such as neuroblastoma, prostate cancer, pancreatic cancer, leukemia, osteosarcoma, hepatoblastoma, lung cancer, colon cancer, breast cancer, skin cancer, thyroid cancer, and / or rhabdoid cancer. JPEG2026522940000099.jpg50170